Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar

Sun Pharmaceutical’s US subsidiary, Caraco Pharmaceuticals, has received a warning letter from the US Food and Drug Administration (USFDA) over quality-control issues. The letter, which was issued on Friday, was a follow-up to the FDA inspection of Caraco’s manufacturing facility in Detroit in May.

The FDA may withhold approval of pending new drug applications of Caraco till the company satisfies the authority’s concerns. Caraco intends to respond to the FDA within 15 days. The company’s Detroit facility manufactures generic drugs. This development does not affect Sun’s sales or approvals for ANDAs in the US. It also does not affect sales for Caraco but might cause a slowdown in approvals for it.

A section of the domestic industry finds a design in Indian companies being penalised in the US market. Recently, USFDA had banned drugs which were produced at Ranbaxy’s two manufacturing plants in India.

Related Shasun Pharmaceuticals Ltd.- (Amalgamation) Links:
1 Year Price Chart
Company Name CMP
Sun Pharma Inds. 665.15
Dr. Reddys Lab 5299.75
Lupin 1154.40
Piramal Enterprises 2432.55
Cadila Healthcare 624.35
View more..
Sensex vs Shasun Pharma
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323